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Abstract
Fn14, the cell surface receptor for TWEAK, is over-expressed in various human solid tumor types
and can be a negative prognostic indicator. We detected Fn14 expression in ~60% of the
melanoma cell lines we tested, including both B-Raf WT and B-RafV600E lines. Tumor tissue
microarray analysis indicated that Fn14 expression was low in normal skin but elevated in
173/190 (92%) of primary melanoma specimens and in 86/150 (58%) of melanoma metastases
tested. We generated both a chemical conjugate composed of the rGel toxin and the anti-Fn14
antibody ITEM-4 (designated ITEM4-rGel) and a humanized, dimeric single-chain antibody of
ITEM-4 fused to rGel (designated hSGZ). Both ITEM4-rGel and hSGZ were highly cytotoxic to a
panel of different melanoma cell lines. Mechanistic studies showed that both immunotoxins
induced melanoma cell necrosis. Also, these immunotoxins could up-regulate the cellular
expression of Fn14 and trigger cell signaling events similar to the Fn14 ligand TWEAK. Finally,
treatment of mice bearing human melanoma MDA-MB-435 xenografts with either ITEM4-rGel or
hSGZ showed significant tumor growth inhibition compared to controls. We conclude that Fn14 is
a novel therapeutic target in melanoma and the hSGZ construct appears to warrant further
development as a novel therapeutic agent against Fn14-positive melanoma.
Correspondence to: Michael G. Rosenblum, Ph.D., Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Unit
1950, 1515 Holcombe Boulevard, Houston, TX, 77030, mrosenbl@mdanderson.org; Phone: 713-792-3554, Jeffrey A. Winkles, Ph.D.,
Departments of Surgery and Physiology, 800 West Baltimore Street, Room 320, University of Maryland School of Medicine,
Baltimore, MD, 21201, jwinkles@som.umaryland.edu; Phone: 410-706-8172; FAX: 410-706-8234.
*Co-Corresponding Authors.
Conflict of Interest
Michael G. Rosenblum is the co-inventor of patents covering this area.
NIH Public Access
Author Manuscript
J Invest Dermatol. Author manuscript; available in PMC 2013 October 01.
Published in final edited form as:
J Invest Dermatol. 2013 April ; 133(4): 1052–1062. doi:10.1038/jid.2012.402.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
Melanoma; Fn14; targeted therapeutics
Introduction
Metastatic melanoma has a poor prognosis, with the median survival for patients with stage
IV disease ranging from 8 to 18 months (Balch et al., 2009). The standard treatment
regimens (DTIC or IL-2) provide only 15–25% response rates (Tsao et al., 2004). Recently,
ipilimumab, an antibody to cytotoxic T-lymphocyte antigen-4 (Sondak et al., 2011), and the
B-RAFV600E inhibitor vemurafenib (Flaherty et al., 2011) were approved by the FDA for
treatment of unresectable or metastatic melanoma. Although there are a number of new
agents and strategies under development, few achieve greater response rates (Ascierto et al.,
2010;Hocker et al., 2008). An effective treatment strategy employing novel therapeutic
approaches for advanced melanoma thus remains a critical imperative.
TWEAK and Fn14 are a TNF superfamily ligand-receptor pair involved in inflammation,
oncogenesis, tumor invasion, migration, survival and resistance to chemotherapy (Burkly et
al., 2007;Winkles, 2008). Fn14 is expressed at relatively low levels in normal tissues, but is
dramatically elevated locally in injured tissues where it plays a role in tissue remodeling
(Winkles, 2008). In addition, Fn14 is highly expressed in breast (Willis et al., 2008) and
brain (Tran et al., 2006) tumors and appears to play a role in the invasive potential of those
diseases. The Fn14 gene has been shown to be overexpressed in numerous other tumor types
(Culp et al., 2010). The correlation between increased Fn14 expression and higher tumor
grade and/or poor prognosis has been documented in brain (Tran et al., 2003;Tran et al.,
2006), breast (Willis et al., 2008), esophageal (Watts et al., 2007;Wang et al., 2006), prostate
(Huang et al., 2011), gastric (Kwon et al., 2012) and bladder (Als et al., 2007) cancer.
The functional relevance of this pathway in oncology suggests that an agent targeted to this
pathway might be a potent cancer therapeutic (Winkles, 2008;Michaelson and Burkly,
2009). Several approaches targeting Fn14 in preclinical models have been explored (Culp et
al., 2010;Michaelson et al., 2011;Zhou et al., 2011). We previously reported that the
antibody-toxin conjugate ITEM4-rGel targeting Fn14 showed significant growth inhibiting
effects against numerous tumor cell lines in vitro and long-term growth suppression in a
human bladder tumor xenograft model (Zhou et al., 2011). These studies clearly suggest that
therapeutic targeting of the TWEAK/Fn14 pathway represents a novel modality to inhibit
tumor growth.
rGel is a type I ribosome-inactivating toxin lacking the ability to efficiently bind to the cell
surface or internalize into mammalian cells (Rosenblum et al., 1995) making this an
excellent payload for targeted therapy approaches. Phase 1 clinical studies of an rGel
immunoconjugate containing the anti-CD33 antibody HuM195 have shown limited
antigenicity and no vascular leak issues with rGel even after repeated administration
(Borthakur, Rosenblum, et al, submitted for publication). For this study, we further
characterized the properties of the ITEM4-rGel conjugate described previously (Zhou et al.,
2011)and generated a new construct consisting of a humanized, dimeric single-chain
antibody of ITEM-4 fused to rGel (designated hSGZ). Here, we present tissue microarray
IHC data which identifies Fn14 as a novel therapeutic target for melanoma. In addition, we
evaluated the cytotoxic efficacy of the ITEM4-rGel and hSGZ immunotoxins against a panel
of melanoma cell lines in vitro and against MDA-MB-435 melanoma cells in vivo.
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Results
Fn14 expression in melanoma cell lines and tumors
Fn14 expression was not detected in normal melanocytes, but it was detected in 20 of 23
melanoma cell lines tested regardless of the tumor stage which the melanoma lines represent
(Fig. 1A). The B-Raf kinase has been shown to represent an important target in melanoma
(Curtin et al., 2005;Davies et al., 2002). Fn14 expression appeared to be independent of B-
Raf gene status in this panel of melanoma cell lines (Fig. 1A). We then examined a
microarray composed of 40 human melanoma cell lines by IHC (Supplementary Table 1).
Compared with the normal human epidermal melanocyte line NHEM-2311, Fn14 was found
to be overexpressed in ~60% of the lines tested. The intensity of protein expression was
slightly higher in the cell lines representing the radial growth phase (RGP). Representative
images from the melanoma cell line microarray staining are shown in Fig. 1B. Fn14
expression on the melanoma cell surface was confirmed using flow cytometry
(Supplementary Fig.1).
We next investigated Fn14 protein expression levels using IHC analysis on a melanoma
progression tumor tissue microarray (TMA) consisting of 462 tissue cores assembled to
reflect samples of tumors from each step in melanocytic tumor progression. A
semiquantitative scoring system of 0 to 3 for expression levels of protein was used to reflect
the staining intensity in tumor cells as illustrated in Fig. 1C. As shown in Table 1, 173/190
(92%) of primary melanoma specimens and 86/150 (58%) of melanoma metastases
specimens scored positive for Fn14. Interestingly, Fn14 expression was also detected in
benign nevi and was elevated in 103/122 (84%) of these samples (Table 1). There was no
significant difference between individual tumor stages for Fn14 expression in this TMA.
Importantly, only 19% (87/462) of the melanoma samples were negative for Fn14
expression. Fn14 expression, presented here, was scored exclusively for the tumor cell
protein expression rather than stroma or immune cells residing in the tumor environment.
Additionally, we did not detect Fn14 staining in primary melanocytes or tissue samples.
Immunotoxin construction, expression and purification
We modeled a single-chain version of the ITEM4-rGel immunotoxin (Zhou et al., 2011) by
isolating RNA from hybridoma cells expressing the ITEM-4 antibody, preparing cDNA, and
amplifying the cDNA encoding murine IgG VH and VL regions. The VH and VL domains
were tethered by a flexible 218 linker (Whitlow et al., 1993) to produce scFv fragments in
either VH-VL or VL-VH orientations. The initial rGel-based immunotoxins consisted of a
flexible L linker (GGGGS) tethering the COOH terminus of scFvIT4 or hscFvIT4 to the
native rGel NH2 terminus. To determine whether the relative orientation of VH and VL
domains impacted the cytotoxic effect on Fn14-expressing tumor cells, the monovalent
immunotoxins were constructed with VH-VL and VL-VH formats. To develop Fn14-targeted
immunotoxins more suitable for clinical use, a humanized single-chain version of ITEM-4
(designated hscFvIT4, Supplementary Fig. 2) specific for Fn14 was successfully produced
and characterized. Using hscFvIT4 and rGel toxin, we next engineered a bivalent
immunotoxin (hSGZ) by adding a COOH-terminal dimerization domain (bZIP) (Carrillo et
al., 2010). Illustrations of the immunotoxin constructs are shown in Fig. 2A. Following
purification, all the rGel-based immunotoxins migrated on SDS-PAGE at the expected
molecular weights of ~55 kDa for monovalent immunotoxins and ~120 kDa for bivalent
immunotoxin (Fig. 2B).
Binding of immunotoxins to Fn14
The binding of ITEM-4, scFvs and immunotoxins to recombinant Fn14 extracellular domain
was assessed by surface plasmon resonance (BIAcore) analysis. We found that ITEM-4,
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scFvIT4, and hscFvIT4 bound to Fn14 with similar equilibrium dissociation constants (Kds)
of ~1.14, 1.19, and 6.25 nmol/L, respectively (Fig. 2C). The immunotoxins ITEM4-rGel,
scFvIT4/rGel (VH-VL), scFvIT4/rGel (VL-VH), hSGZ (monomer) and hSGZ (dimer) bound
to Fn14 with equilibrium dissociation constants (Kds) of 2.5, 1.08, 2.3, 2.5 and 1.4 nmol/L,
respectively (Fig. 2C). Purified rGel did not bind to Fn14 in this assay. Both immunotoxins
showed specific binding to MDA-MB-435 cells compared to the background of binding to
Fn14-deficient mouse embryonic fibroblasts (MEF 3.5 −/−) in an enzyme-linked
immunosorbent assay (ELISA)-based binding assay (Supplementary Fig. 3A).
Conversion into a bivalent format improves the cytotoxic effects of scFvIT4/rGel
We investigated whether ITEM4-rGel and the scFvIT4/rGel-based fusion proteins had
similar cytotoxicity against various melanoma cell lines. To quantitatively compare the
cytotoxicity of bivalent and monovalent formats, dose-dependent growth inhibition curves
were established on MDA-MB-435 cells (Fig. 2D). An IC50 value of 0.006 nmol/L was
obtained for ITEM4-rGel. IC50 values of 12.0, 3.6 and 18.3 nmol/L were obtained for
scFvIT4/rGel (VH-VL), scFvIT4/rGel (VL-VH) (Fig. 2D) and hSGZ (monomer)
(Supplementary Fig. 3B), respectively. An IC50 value of 0.008 nmol/L was calculated for
hSGZ dimer (Fig. 2D and Supplementary Fig. 3B). Thus, a 2287-fold reduction in IC50
value was achieved by converting monomeric hSGZ into homodimeric, bivalent hSGZ.
Unless otherwise specified, hSGZ refers to the dimeric construct.
ITEM4-rGel and hSGZ demonstrated significant cytotoxicity against melanoma cell lines
(IC50 ranged from 0.1 pmol/L-1.1 nmol/L) and they were 2.2 to 2.8 ×105 fold more potent
than free rGel (Supplementary Table 2). By comparison, the cytotoxic effects of these
immunotoxins on Fn14-negative MEF3.5 −/− cells was similar to that of free rGel
(Supplementary Table 2). As shown in Fig. 2E, pre-incubation with 1 µmol/L ITEM-4 for 4
h shifted the ITEM4-rGel and hSGZ induced cytotoxicity to that of the rGel curve in WM35
cells.
Cellular uptake of immunotoxins
Immunofluorescence staining was done on MDA-MB-435 and MEF 3.5−/− cells after
exposure to the immunotoxins. As shown in Fig. 2F, the rGel moiety (green) of both
immunotoxins was observed primarily in the cytosol of MDA-MB-435 cells. Internalization
did not occur in MEF 3.5−/− cells (data not shown).
Mechanistic studies of immunotoxin cytotoxic effects
Immunotoxins did not induce apoptosis or autophagy when added to Fn14-positive
melanoma cells (Supplementary Fig. 4). To assess whether necrotic cell death was induced,
we performed a PI exclusion assay which investigates the early loss of plasma membrane
integrity that occurs during classical necrosis (Do et al., 2003). MDA-MB-435 and
AAB-527 cells displayed an increasing loss of plasma membrane integrity after treatment
with ITEM4-rGel or hSGZ but not treatment with ITEM-4 or rGel (Fig. 3A). In contrast,
immunotoxins did not induce necrosis when added to MEF3.5−/− cells (Supplementary Fig.
4C). For further confirmation of a necrotic response, the lactate dehydrogenase (LDH)
release assay was used to measure cell lysis (Do et al., 2003). Immunotoxin-induced LDH
release was found to be both time- and dose-dependent for both cell lines studied; however,
treatment with ITEM-4 and rGel did not induce LDH release in this assay (Fig. 3B).
A common event in numerous forms of cell death is mitochondrial outer membrane
permeabilization (MOMP) which results in escape of mitochondrial proteins that are toxic
within the cytosol, then a rapid decline in ATP production and the generation of reactive
oxygen species (ROS) (Kroemer and Martin, 2005). We also found that exposure of MDA-
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MB-435 and AAB-527 cells to ITEM4-rGel and hSGZ but not ITEM-4 or rGel resulted in
mitochondrial membrane depolarization using the mitochondrial dye JC-1 (Fig. 3C). This
finding indicates that the immunotoxins may promote ROS release, which could contribute
to cell death induced by these constructs.
The ITEM-4 antibody and derivative immunotoxins can up-regulate Fn14 expression and
activate the NF-κB pathway
It has been reported that TWEAK treatment of human glioma (Tran et al., 2006) and
prostate (Huang et al., 2011) tumor cells increases Fn14 gene expression. Since ITEM-4 has
agonistic activity (Nakayama et al., 2003) we considered the possibility that the ITEM4-
based immunotoxins might actually increase expression of their cell surface target. ITEM-4
treatment increased Fn14 expression in all cell lines tested (Fig. 4A and Supplementary Fig.
5A, B). Since Fn14 is an NF-κB target gene (Tran et al., 2006), we tested if ITEM-4 could
activate the NF-κB pathway using a HEK293/NFκB-luc/Fn14 luciferase reporter cell line.
ITEM-4, but not isotype-matched control IgG, dose-dependently resulted in induction of the
NF-κB pathway reporter gene (Fig. 4B). Consistent with this data, we found that ITEM4-
rGel and hSGZ can induce both the classical (not shown) and alternative NF-κB signaling
pathways as well as Fn14 expression after treatment of MDA-MB-435 cells (Fig. 4C and
4D) and AAB-527 cells (Supplementary Fig. 5C), similar to the effect observed upon
treatment with ITEM-4 and TWEAK. We also detected increase Fn14 levels on the
melanoma cell surface after immunotoxin treatment (Supplementary Fig. 5E). Finally,
ITEM4-rGel and hSGZ can also induce expression of additional NF-κB-regulated genes,
including IL-8 and TNF-α (Supplementary Fig. 5D). Taken together, the data indicate that
the ITEM4-rGel and hSGZ exhibit agonistic activity, including activation of the NF-κB
signaling pathway and induction of Fn14, IL-8 and TNFα production, analogous to the
effects of TWEAK.
hSGZ exhibited comparative in vivo tumor growth inhibition activity to ITEM4-rGel
We next examined the effect of immunotoxins on the growth of established human
melanoma (MDA-MB-435-Luc) xenografts assessed by either caliper measurement or
bioluminescence imaging (BLI). Significant tumor growth inhibition was observed at doses
of 30 or 60 mg/kg of the ITEM4-rGel (Fig. 5A and Supplementary Fig. 6B) and 25 or 50
mg/kg of the hSGZ construct (Fig. 5B and Supplementary Fig. 6D) compared to saline-
treated controls (P < 0.005). Mice treated with 60 mg/kg ITEM-4 also had less tumor growth
relative to the saline control; however, this difference bordered on statistical significance (P
= 0.049). The representative BLI images of the tumors on selected days clearly
demonstrated the antitumor properties of the ITEM4-rGel (Supplementary Fig. 6A) and
hSGZ (Fig. 5C). We also found that hSGZ treatment upregulated Fn14 expression in vivo as
assayed by Western blot analysis of tumor tissues (Fig. 5D). Immunofluorescence staining
confirmed that ITEM4-rGel and hSGZ localized specifically in tumor tissue and no
nonspecific staining was observed in tumors after administration of ITEM-4 and saline
detected by anti-rGel antibody (Fig. 5E). This suggests that the ITEM4-rGel and hSGZ can
target tumor cells overexpressing Fn14 in vivo. Toxicity was monitored by frequent body
weight measurements in groups of mice treated with ITEM4-rGel or hSGZ. Body weights
showed less than a 20% change in any of the treated mice over the duration of the
experiment for ITEM4-rGel (Supplementary Fig. 6C) and hSGZ (Supplementary Fig. 6E)
administration.
Discussion
This study identifies Fn14 as a potential new target for melanoma therapy. We first explored
the expression characteristics of Fn14 in a large set of melanoma cell lines representing
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various stages of disease progression. Our results showed that while increased expression of
Fn14 in melanoma cell lines is suggestive of a link to melanoma, even more notable is that
in some melanoma cell lines (such as WM35 P1.N1, WM35 P2.N1) there appears to be a
link between Fn14 expression and tumor progression. Nevi may further progress to
melanoma or can regress by differentiating to cell types that have been histopathologically
defined as (non malignant) Schwann cells (Clark, Jr. et al., 1984). Interestingly, Fn14 was
expressed at a similar frequency in benign nevi and in primary melanomas, but with a lower
frequency in metastatic melanomas suggesting that it is upregulated in early melanoma
tumorigenesis. The high percentage of Fn14 expression in melanoma prompted us to
develop the Fn14-targeted immunotoxins as anti-melanoma therapeutic agents.
We constructed different formats of immunotoxins and all of them showed high binding to
Fn14. The conversion of monovalent hSGZ immunotoxin into a bivalent format by adding a
COOH-terminal dimerization domain dramatically enhanced the potency of this construct in
vitro (Fig. 2D and Supplementary Fig. 3B), suggesting an effect of higher order cross-
linking of Fn14 molecules on the cell surface induced by bivalent binding.
Cell death caused by Fn14-targeted immunotoxins could be the result of a combination of
activation of the intrinsic cytotoxicity related to the Fn14 pathway (Michaelson and Burkly,
2009) and the inhibition of protein synthesis by the rGel toxin. We previously demonstrated
that the ITEM4-rGel immunotoxin killed T-24 bladder tumor cells through an apoptotic
mechanism with release of HMGB1 protein (Zhou et al., 2011). However, the cytotoxic
effects of ITEM4-rGel and hSGZ on melanoma cells occurred through a cellular necrosis
mechanism and involved LDH release. Taken together, these data suggest that Fn14-targeted
immunotoxins can induce cell death through different mechanisms and the effects appear to
be cell type-dependent. The necrotic cell death mechanism observed after melanoma cell
exposure to the Fn14-targeted immunotoxins may also be the result of the well-known
intrinsic resistance of these cells to apoptosis (Soengas and Lowe, 2003).
In general, the efficacy of antibody-based therapies can be hampered as the tumor cells
adopt defensive tactics such as shedding of the target antigen/receptor and masking to
escape immune surveillance. Target antigen/receptor expression may also be down-
regulated in vivo due to therapy with other agents. We found that Fn14 expression was up-
regulated by ITEM-4 treatment. This effect was also observed with the natural Fn14 ligand
TWEAK and the immunotoxins. Consistent with our in vitro results, Fn14 expression in
xenograft tumors was up-regulated by hSGZ administration (Fig.5D). We also showed that,
like TWEAK, Fn14-targeted immunotoxins are capable of inducing NF-κB pathway
activation. Signaling by the TWEAK/Fn14 axis appears to exert either pro-tumorigenic or
anti-tumorigenic effects depending on the particular microenvironment (Michaelson and
Burkly, 2009;Winkles, 2008). It is important to note that no enhancement in tumor growth
was observed following ITEM-4 treatment in our xenograft models. This result is consistent
with prior data indicating that administration of TWEAK resulted in dramatic reduction in
tumor growth in xenograft models (Michaelson et al., 2011). ITEM4-rGel was found to be
slightly more potent than hSGZ in the xenograft model (Fig. 5A and B, ITEM4-rGel 30mg/
kg treated group vs hSGZ 50 mg/kg treated group). The better potency observed with
ITEM4-rGel could be due to the longer half-life of the larger IgG conjugate in vivo
(Zalevsky et al., 2010), antibody-dependent cellular cytotoxicity (ADCC) of ITEM-4
(Nakayama et al., 2003) and a more efficient agonistic activity of the IgG construct in this
specific setting. Given the cross-species reactivity of ITEM-4 to mouse Fn14, the toxicity of
ITEM4-rGel or hSGZ on non-tumor tissues in vivo was found to be minimal and this may
be reflective of expected toxicity in patients.
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The abundant overexpression of Fn14 in melanoma makes it an attractive cell surface target
for agents such as immunotoxins. hSGZ, the humanized counterpart of ITEM4-rGel, has a
unique cytotoxicity to melanoma and these findings, together with its in vivo anti-tumor
efficacy, suggest that hSGZ warrants further development as a novel therapeutic agent
against Fn14-positive melanoma.
Materials and Methods
Cell lines and reagents
Human melanoma cell lines (WM3211, Sbcl2, WM1346, WM1361A, WM1366, WM793,
WM983A, MeWo, WM46, A375, WM983B, SK-MEL-3, SK-MEL-24, SK-MEL-28, SK-
MEL-32, WM35, WM35P2N1, SB2, SK-MEL-1, SK-MEL-5) were maintained in RPMI
1640 medium (HyClone, Logan, UT). Melanoma cell lines A375M, AAB-527 and Fn14-
deficient mouse embryonic fibroblasts (MEF 3.5−/−) were maintained in DMEM
(HyClone). All medium contained 10% FBS. The luciferase-expressing human melanoma
cell line MDA-MB-435-Luc was derived from MDA-MB-435 cells as previously reported
(Murray et al., 2003). The murine IgG2b/κ monoclonal antibody ITEM-4 directed against
human and mouse Fn14 receptor (Nakayama et al., 2003) and the generation of
immunoconjugate ITEM4-rGel have been described previously (Zhou et al., 2011).
Recombinant human TWEAK was purchased from R&D Systems (Minneapolis, MN).
Melanoma cell line microarray, TMA and immunohistochemistry
A human melanoma cell line microarray was established at M.D. Anderson Cancer Center
(MDACC). The melanocytic tumor progression TMA was designed to provide samples of
tumors from each step in melanocytic tumor progression (Nazarian et al., 2010). The TMA
contains 462 tissue cores from 169 patients, consisting of benign nevi (122 cores from 35
patients), primary cutaneous melanomas (190 cores from 59 patients), melanoma metastases
to lymph nodes (60 cores from 29 patients), and melanoma metastases to visceral organs (90
cores from 46 patients). Acral, mucosal, and uveal melanomas were excluded from this
TMA (Nazarian et al., 2010). Immunohistochemical analysis for Fn14 was performed as
previously described using 2.5 µg/ml of the Fn14 monoclonal antibody P4A8 and an isotype
matched murine IgG as control (Tran et al., 2003). Immunolabeling was scored separately
for 2 variables; first, for number of positive melanoma cells; second, for the overall intensity
of immunoreactivity of the positive cells. Scoring for number of positive tumor cells was
defined as follows: 0, <5% positive cells; 1, 5–25% positive cells; 2, >25– 75% positive
cells; 3, > 75% positive cells. Intensity scoring was defined as follows; 0, no staining; 1,
light staining; 2, moderate staining and 3, intense staining. The slides were independently
interpreted by 2 readers without knowledge of the clinical data. Any discrepancies in scores
were subsequently reconciled.
In vitro studies
The following methods are described in Supplementary Materials and Methods: cloning and
humanization of single-chain Fv (scFv); plasmid construction; protein expression in E. coli;
isolation and purification of fusion immunotoxins; surface plasmon resonance assay (Brown
et al., 2006); ELISA (Cao et al., 2009) and internalization analyses (Zhou et al., 2011);
reticulocyte lysate in vitro translation assay (Hale, 2001); in vitro cytotoxicity assay (Zhou
et al., 2011); flow cytometry analysis (Zhou et al., 2011); PI exclusion assay (Do et al.,
2003); LDH release assay; mitochondrial membrane depolarization assay; apoptosis assay;
Western blot analysis; and NF-κB pathway luciferase reporter assay (Brown et al., 2010).
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In vivo efficacy studies
Animal procedures were conducted according to a protocol approved by the AALAC-
approved Animal Care and Use Facility at MDACC. Female BALB/c nude mice (Harlan
Sprague Dawley Inc, Indianapolis, IN), 8 weeks old, were injected (hind flank)
subcutaneously with MDA-MB-435-LUC cells (1 × 107 cells per mouse; suspended in 100
µL of PBS mixed with 100 µL BD Matrigel). Once tumors reached a mean volume of ~200
mm3, animals (5 mice per group) were treated (i.v. via tail vein) with PBS, ITEM-4 or with
immunotoxins. Animals were monitored and tumors were measured every 2–3 days. Data
are presented as mean tumor volume (mm3) ± SD.
BLI
In vivo BLI was conducted using the IVIS100 system with Living Image acquisition and
analysis software (Caliper Life Sciences, Hopkinton, MA). Anesthetized mice were i.p.
injected with 75 mg/kg D-luciferin (Gold Biotechnology, Inc., St.Louis, MO) and imaged
for 10 minutes after luciferin injection.
Localization of ITEM4-rGel and hSGZ in tumor tissue
Twenty-four hours after i.v. injection of ITEM-4, ITEM4-rGel or hSGZ, mice were
sacrificed and tumor samples were collected and frozen immediately for sectioning.
Localization of ITEM4-rGel and hSGZ in tumor tissues was assessed as previously
described (Zhou et al., 2011).
Statistical analysis
A number of statistical methods were employed for the analysis of the microarray data.
Cohen’s Kappa coefficient was estimated to assess the degree of agreement between
duplicate readings for the same sample. In addition, Bowker’s test of symmetry was applied
to the analyses. To determine the relationship between Fn14 readings and disease stages, the
Fn14 percentages or intensity scores were treated as ordinal responses and an ordinal
regression model accounting for repeated measurements within each sample was used to fit
the Fn14 scores. All computations including Chi-squared tests were performed in SAS v9.2.
P values were obtained using 1-tailed t test with 95% confidence interval for evaluation of
the statistical significance compared with the controls in the animal studies. P < 0.05 was
considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviation list
TNF Tumor necrosis factor
TWEAK TNF-like weak inducer of apoptosis
Fn14 fibroblast growth factor -inducible protein 14
rGel recombinant gelonin
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Figure 1.
Fn14 is overexpressed in melanoma cell lines and human tumor samples. A) Cell lines were
assayed for Fn14 and tubulin levels by Western blot. B-RAF status is indicated: WT, wild
type; MT, V600E mutant. Abbreviations: RGP, radial-growth phase; VGP, vertical-growth
phase. B) Fn14 expression in melanoma cell lines was also assayed using a cell line
microarray and an anti-Fn14 antibody. Images from four of the lines are shown. Scale bar =
100 µm. C) Paraffin sections of melanocytic tumor progression tissue microarray were
immunostained with an anti-Fn14 antibody. A relative staining intensity (0 – 3+) was
assigned and a melanoma specimen representing each intensity level is presented. Scale bar
= 100 µm.
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Figure 2.
Characterization of immunotoxins targeting the Fn14 receptor. A) Schematic diagram of
immunotoxin constructs containing scFvIT4 and hscFvIT4, peptide linker (218 and L), rGel
toxin and bZIP dimerization domain. The amino acid sequence of the linker and bZIP
domain is shown. B) SDS-PAGE analysis of purified scFvIT4 and immunotoxins in non-
reducing conditions. C) Surface plasmon resonance analysis of scFvIT4, hscFvIT4, ITEM-4
and immunotoxin binding to recombinant Fn14 extracellular domain. D) Various
concentrations of rGel, ITEM4-rGel, two different formats of fusion immunotoxins, and
bivalent format of hSGZ were added to MDA-MB-435 cells and cytotoxicity was measured
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as described in Materials and Methods. E) Pretreated WM35 cells with ITEM-4 abrogated
the cytotoxic effects of ITEM4-rGel and hSGZ. F) Internalization of ITEM4-rGel and hSGZ
into MDA-MB-435 cells. Scale bar = 50 µm.
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Figure 3.
Cell death induced by ITEM4-rGel and hSGZ resembles necrosis. A) PI exclusion assay for
ITEM4-rGel and hSGZ after 48 or 24 h of exposure in MDA-MB-435 and AAB-527 cells,
respectively. The percentage of cells with PI staining is indicated within each panel. B) LDH
release assay for ITEM4-rGel and hSGZ after 24 and 48 h of treatment in MDA-MB-435
and AAB-527 cells. Results represent mean ± SD, n = 3. C) MDA-MB-435 and AAB527
cells were either left untreated or treated with 1 nmol/L ITEM-4, ITEM4-rGel or hSGZ for
48 h and then mitochondrial membrane depolarization was assayed by JC-1 staining
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followed by flow cytometric analysis. Numbers in the lower right quadrants, percentage of
cells with JC-1 green fluorescence.
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Figure 4.
ITEM4-rGel and hSGZ exhibit agonist activity. A) Indicated cells were either left untreated
or treated with 10 Wg/ml ITEM-4 for 12 h. Fn14 or GAPDH levels were analyzed by
Western blot. B) HEK293/NFκB-luc/Fn14 cells were either left untreated or treated with the
indicated concentration of ITEM-4 or mouse IgG for 6 h. NF-κB reporter activation was
measured using a luminometer. The values shown are mean ± S.D. (n=3. *, p < 0.05).
MDA-MB-435 cells were treated with the indicated concentrations of ITEM4-rGel, hSGZ,
ITEM-4 or TWEAK for 48 h (C) or were treated with 1 nmol/L of ITEM4-rGel or hSGZ for
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the indicated time points (D). Cells were analyzed for Fn14, β-actin, and/or NF-κB p100
processing to p52 by Western blot.
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Figure 5.
Antitumor activity of Fn14-targeted immunotoxins against MDA-MB-435-LUC tumor
xenografts in mice. Tumor growth during treatment (i.v. injection) of MDA-MB-435 flank
tumors with PBS, ITEM-4 or ITEM4-rGel (A) or with PBS or hSGZ (B) on the indicated
days (arrows) with the indicated total doses. For both A) and B), mean tumor volume was
calculated using the formula W×L×H as measured by calipers. Data are mean ± SEM (n=5).
C) The BLI images of tumor burden from the xenograft experiment in (B) are shown on
selected days. D) Tumor tissues from the xenograft experiment in (B) were analyzed for
Fn14 and GAPDH expression by Western blot. E) Immunofluorescence staining of MDA-
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MB-435 tumor samples using an anti-rGel antibody after PBS, ITEM-4, ITEM4-rGel or
hSGZ administration.
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